Journal article
PHARMACOLOGICAL THERAPY FOR INFLAMMATORY BOWEL-DISEASE
American family physician, v 51(8), pp 1971-1975
01 Jun 1995
PMID: 7762487
Featured in Collection : UN Sustainable Development Goals @ Drexel
Abstract
The pharmacologic management of ulcerative colitis and Crohn's disease is usually carried out in a stepwise fashion. Initially, oral sulfasalazine or 5-aminosalicylic acid (5-ASA) products are given and, for patients with rectal disease, treatment may include topical therapy with either 5-ASA enemas or hydrocortisone suppositories. Patients with more active inflammatory disorders may also require oral corticosteroid therapy. Patients with fulminant disease may require intravenous steroids and antibiotic therapy. If frequent relapses prevent discontinuation or significant reduction of prednisone therapy, azathioprine or 6-mercaptopurine may offer benefit as steroid-sparing agents. Also, intravenous cyclosporine has proved useful in patients with fulminant inflammatory bower disease that is unresponsive to other therapy. Metronidazole has value in the treatment of perianal disease secondary to Crohn's disease. Balancing the risks and benefits of single or combination therapy is an ongoing challenge in patients with inflammatory bowel disease.
Metrics
6 Record Views
Details
- Title
- PHARMACOLOGICAL THERAPY FOR INFLAMMATORY BOWEL-DISEASE
- Creators
- S HirschfeldH R Clearfield
- Publication Details
- American family physician, v 51(8), pp 1971-1975
- Publisher
- Amer Acad Family Physicians
- Number of pages
- 5
- Resource Type
- Journal article
- Language
- English
- Academic Unit
- [Retired Faculty]
- Web of Science ID
- WOS:A1995RB38100020
- Scopus ID
- 2-s2.0-0029026833
- Other Identifier
- 991019184313304721
UN Sustainable Development Goals (SDGs)
This publication has contributed to the advancement of the following goals:
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool:
- Web of Science research areas
- Primary Health Care